Dalfampridine API Manufacturers

Looking for Dalfampridine API 504-24-5?

Description:

Here you will find a list of producers, manufacturers and traders of Dalfampridine. You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.

API | Excipient name:

Dalfampridine 

Synonyms:

4-Pyridylamine , Ampyra , Avitrol , Dalfampridine , Fampridina , Fampridine , Fampridine-SR , Fampridinum , gamma-Aminopyridine , P-Aminopyridine , Fampridin , 4-Aminopyridin  

Cas Number:

504-24-5 

DrugBank number:

DB06637 

Unique Ingredient Identifier:

BH3B64OKL9

Dalfampridine is a type of Potassium channel blockers

Potassium channel blockers belong to the subcategory of pharmaceutical active pharmaceutical ingredients (APIs) used in the development of drugs targeting potassium channels. These blockers play a crucial role in the regulation of various physiological processes in the human body. Potassium channels are membrane proteins that allow the selective passage of potassium ions across cell membranes. They are involved in maintaining the electrical activity of cells, including nerve cells, muscle cells, and cardiac cells. By selectively blocking these channels, potassium channel blockers can modulate cellular excitability and influence various physiological functions.

In the field of medicine, potassium channel blockers have found application in the treatment of several disorders, including cardiovascular diseases, epilepsy, and neuropathic pain. By inhibiting the potassium channels, these blockers can effectively regulate abnormal electrical activity in the heart, brain, and other tissues.

Pharmaceutical companies employ various strategies to develop potassium channel blockers as API for drug formulation. These strategies involve chemical synthesis, molecular modeling, and structure-activity relationship studies to design compounds with high selectivity and affinity for specific potassium channels.

The development of potassium channel blockers requires rigorous testing to evaluate their pharmacokinetic and pharmacodynamic properties, safety, and efficacy. Preclinical and clinical studies are conducted to assess the drug's therapeutic potential and identify any potential adverse effects.

In conclusion, potassium channel blockers are an important subcategory of pharmaceutical APIs used in the development of drugs targeting potassium channels. Their ability to modulate cellular excitability makes them valuable therapeutic agents for treating various disorders, particularly those involving abnormal electrical activity in the body.

Dalfampridine (Potassium channel blockers), classified under Anti-arrhythmics

Anti-arrhythmics belong to the pharmaceutical API category designed to treat irregular heart rhythms, also known as arrhythmias. These medications work by targeting the electrical signals in the heart, helping to regulate the heart's rhythm and restore it to a normal, steady beat.

Anti-arrhythmics are crucial in managing various types of arrhythmias, such as atrial fibrillation, ventricular tachycardia, and supraventricular tachycardia. These conditions can pose serious risks, including an increased likelihood of stroke or heart failure. Hence, anti-arrhythmics play a vital role in improving patient outcomes and reducing these associated risks.

Pharmaceutical companies develop anti-arrhythmic APIs, which are the active ingredients used to formulate the final medications. These APIs undergo rigorous testing and quality control measures to ensure their safety, efficacy, and consistent performance. They are manufactured in accordance with Good Manufacturing Practices (GMP) guidelines to meet the highest quality standards.

Healthcare professionals prescribe anti-arrhythmics based on the specific arrhythmia type, severity, and individual patient factors. These APIs can be formulated into different dosage forms, including tablets, capsules, or intravenous solutions, depending on the desired route of administration and patient requirements.

It is important to note that anti-arrhythmics are prescription-only medications and should only be used under medical supervision. Patients using these medications must follow their healthcare provider's instructions and regularly monitor their heart rhythm to ensure optimal treatment effectiveness and minimize potential side effects.

In conclusion, anti-arrhythmics are a crucial category of pharmaceutical APIs used to treat various types of irregular heart rhythms. They are formulated into medications that help regulate the heart's electrical signals, reduce associated risks, and improve patient outcomes.

• Caesar & Loretz GmbH (CAELO) from Germany, product country of origin Germany
• Attix Pharmaceuticals from United States, product country of origin China
• Industriale Chimica from Italy, product country of origin Unknown
• Alkem Labs. from India, product country of origin India
• Intas Pharma from United Kingdom, product country of origin Unknown
• Micro Labs from India, product country of origin India
• Procos from Italy, product country of origin Italy
• Sun Pharma from India, product country of origin India
• Jubilant Generics from India, product country of origin India

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.